 |
Previous Article | Next Article 
Volume 17, Number 18,
Issue of September 15, 1997
pp. 7007-7016
Copyright ©1997 Society for Neuroscience
Trk Receptors Function As Rapid Retrograde Signal Carriers in the
Adult Nervous System
Anita Bhattacharyya1,
Fiona L. Watson2,
Tatum A. Bradlee1,
Scott L. Pomeroy3,
Charles D. Stiles1, and
Rosalind A. Segal2
1 Dana-Farber Cancer Institute and Department of
Microbiology and Molecular Genetics, Harvard Medical School, Boston,
Massachusetts 02115, 2 Department of Neurology, Beth
Israel-Deaconess Medical Center and Program in Neuroscience, Harvard
Medical School, Boston, Massachusetts 02115, and 3 Division
of Neuroscience, Department of Neurology, Children's Hospital, and
Program in Neuroscience, Harvard Medical School, Boston, Massachusetts
02115
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES
ABSTRACT
During development target-derived neurotrophins promote the
survival of neurons. However, mature neurons no longer depend on the
target for survival. Do target-derived neurotrophins retain retrograde
signaling functions in mature neurons, and, if so, how are they
executed? We addressed this question by using a
phosphotyrosine-directed antibody to locate activated Trk receptors in
adult rat sciatic nerve. We show that catalytically active Trk
receptors are located within the axon of adult rat sciatic nerve and
that they are distributed throughout the length of the axons. These
catalytically active receptors are phosphorylated on tyrosine at a
position that couples them to the signal-generating proteins Ras and
PI3 kinase. Neurotrophin applied at sciatic nerve terminals increases
both catalytic activity and phosphorylation state of Trk receptors at
distant points within the axons. Trk activation initiated at the nerve
terminals propagates through the axon toward the nerve cell body at an
initial rate that exceeds that of conventional vesicular transport.
However, our data suggest that this rapid signal is nevertheless
vesicle-associated. Thus, in mature nerves, activated Trk receptors
function as rapid retrograde signal carriers to execute remote
responses to target-derived neurotrophins.
Key words:
neurotrophin;
Trk;
sciatic nerve;
receptor tyrosine
kinase;
signal transduction
INTRODUCTION
Target-derived neurotrophins evoke
diverse responses in presynaptic neurons, including effects on
survival, neurite outgrowth, and synaptic modulation (Levi-Montalcini
and Angeletti, 1968 ; Levi-Montalcini, 1987 ; Barde, 1989 ; Snider and
Johnson, 1989 ; Deckwerth and Johnson, 1993 ; Lai et al., 1993 ; Raffioni
et al., 1993 ; Vogel, 1993 ; Mehler and Kessler, 1994 ). Some of these
effects are local in nature (Campenot, 1982 , 1987 ; Diamond et al.,
1992b ), whereas other responses require that neurotrophins, presented at the nerve terminals, initiate an intracellular signal that travels
through the axon to the remote cell body (Hendry and Crouch, 1991 ;
Campenot, 1994 ).
Both local and long distance neurotrophic functions are initiated by
ligand binding and activation of receptor tyrosine kinases: TrkA for
NGF, TrkB for BDNF, and neurotrophin (NT) NT4/5 and TrkC for NT3
(Bothwell, 1991 ; Barbacid, 1994 ). The activated receptors initiate
local signaling at the membrane and also initiate signaling cascades
that traverse the cytoplasm and culminate in the nucleus with
transcriptional changes (Segal and Greenberg, 1996 ). Three models have
been proposed to explain how signal transduction pathways convey a
retrograde signal from a nerve terminal through an axon to a distant
cell body (Hendry and Crouch, 1993 ; Campenot, 1994 ). The central
feature of the first model is that target-derived neurotrophins are
transported in vesicles from nerve terminals to cell bodies. On arrival
at the cell body, neurotrophin receptors are activated and initiate
signal transduction pathways. This model predicts that retrograde
transport of neurotrophin to the cell body is sufficient for signaling
and that neurotrophin receptors are activated exclusively within the
cell body.
A second model is that neurotrophins bind and activate receptors
at nerve terminals. Activated receptors then interact with and activate
downstream mediators. In this model the axon could be considered an
extension of the cell body cytoplasm, with active vesicular transport
conveying downstream signaling molecules to the nucleus to complete the
signal transduction cascade (Johanson et al., 1995 ). One prediction of
this model is that neurotrophins activate receptors only at the nerve
endings.
In a third model, receptors are activated by neurotrophins at nerve
terminals and thereby initiate local signaling pathways. However,
internalized activated receptors also are transported through the axon
toward the nerve cell body. Activated receptors, alone or in a
ligand-receptor complex, continue to activate downstream signal
transduction pathways en route. Indeed, neurotrophin receptors are
internalized after activation (Hosang and Shooter, 1987 ; Kahle et al.,
1994 ) and undergo retrograde transport (Johnson et al., 1987 ; Raivich
et al., 1991 ; Loy et al., 1994 ; Ehlers et al., 1995 ). Receptor
internalization generally is considered a component of signal
termination and receptor recycling rather than signal transduction (Sorkin and Waters, 1993 ). However, the possibility that Trk
internalization might be part of a signaling pathway is bolstered by
recent demonstrations that vesicle-associated Trk receptors in PC12
cells are phosphorylated (Grimes et al., 1996 ) and that receptor
endocytosis actually stimulates some signaling molecules (Vieria et
al., 1996 ). A prediction of this model for retrograde signaling is that
activated receptors are distributed throughout the axon and are engaged
in signal transduction.
Each model for retrograde signaling predicts a distinct distribution of
activated neurotrophin receptors. To test these models, we used an
antibody that recognizes phosphorylated Trks (Segal et al., 1996 ) to
visualize activated receptors within adult rat sciatic nerve. We found
that activated Trks are distributed along the length of sciatic nerve
axons and that phosphorylation state and catalytic activity of axonal
Trk receptors are regulated by neurotrophins applied at nerve
terminals. The response to exogenous neurotrophin is surprisingly
rapid. These data suggest that phosphorylated Trks propagate a
retrograde signal in axons in the adult nervous system.
MATERIALS AND METHODS
Reagents
Anti-pY490 polyclonal antisera were raised against a
phosphopeptide (VIENPQpYFGITNS) corresponding to the conserved Shc
recognition site of all Trks (Segal et al., 1996 ). Anti-Trk and
anti-TrkB were generous gifts from Dr. David Kaplan (Montréal
Neurological Institute, Montréal, Québec, Canada). Anti-Trk
is an antibody to the C-terminal tail of Trk (Hempstead et al., 1992 ).
The TrkB-specific antibody was raised against a peptide in the
intracellular domain of TrkB. The anti-phosphotyrosine antibody (4G10)
(Druker et al., 1989 ) was a gift of Dr. Thomas Roberts (Dana-Farber
Cancer Institute, Boston, MA). The Shc antibody was purchased from
Upstate Biologicals (UBI, Lake Placid, NY). Recombinant human BDNF and
NT3 were generous gifts of Dr. Andrew Welcher and Amgen (Thousand Oaks,
CA). NGF was purchased from Life Technologies (Grand Island, NY). The
peptides used for competition experiments were generated as described
(Segal et al., 1996 ): the Y490 unphosphorylated peptide (VIENPQYFGITNS) and the NPXpY site of the erbB2 receptor (AENPEpYLGLDVPV).
Immunohistochemistry
Trk 3T3 cells were plated onto poly-D-lysine-coated
coverslips in 24-well tissue culture plates. Quiescent cells were
stimulated by the addition of 100 ng/ml neurotrophin or 0.1% BSA in
PBS for 5 min; stimulation with vehicle alone served as a control.
Untransfected NIH3T3 cells were stimulated with a cocktail of 50 ng/ml
of each neurotrophin. The cells were fixed for 20 min in 4%
paraformaldehyde in TBS and 1 mM sodium ortho vanadate,
washed with TBS, and then permeabilized with 5% normal goat serum
(NGS) and 0.5% NP-40 in TBS/vanadate for 1 hr. Cells were washed
briefly and incubated with anti-pY490 (1:25) in 2% NGS in TBS/vanadate
overnight at 4°C. For anti-pY490 staining and competition, the
antibody was preincubated for 30 min at room temperature with a 100 nM concentration of the phosphopeptide immunogen, the
corresponding unphosphorylated peptide, or a phosphopeptide
representing the NPXY domain of the erbB2 receptor tyrosine kinase.
Staining was visualized by avidin-biotin-HRP (Vector Labs,
Burlingame, CA), followed by diaminobenzidine (DAB; Sigma, St. Louis,
MO), according to the manufacturers' procedures. Coverslips were
mounted in Immumount (Shandon, Pittsburgh, PA).
Immunostaining of sciatic nerves. Anesthetized adult male
Sprague Dawley rats (230-300 gm) were perfused intracardially with 4%
paraformaldehyde in TBS/vanadate. Sciatic nerves were harvested and
post-fixed for 6 hr. After incubation in 30% sucrose, nerves were
embedded in Tissue Tek embedding media (Miles, Elkhart, IN) and frozen
on dry ice. Cryostat sections (7.5-10 µm thickness) were cut and
mounted onto coated slides (Fisher, Springfield, NJ). Then the sections
were stained with the pY490 antibody, as described above. For double
labeling, sections were incubated with both anti-pY490 and
anti- -acetylated tubulin (6-11-B1, Sigma) or anti-clathrin (ICN
Biomedicals, Costa Mesa, CA) overnight at 4°C, followed by incubation
with Cy3-conjugated goat anti-rabbit IgG and Cy2-conjugated goat
anti-mouse IgG (Jackson Immunochemicals, West Grove, PA) in 2% NGS in
TBS/vanadate for 1 hr.
Immunostaining of wild-type and BDNF / hippocampus. BDNF
/ and +/+ littermates were identified by PCR analysis. At postnatal day 14, anesthetized animals were perfused with 4% paraformaldehyde in
PBS. Brains were removed, post-fixed in paraformaldehyde, and then
infiltrated with sucrose. Coronal cryostat sections (15 µm) were cut
and immunostained with pY490 and Cy3, as described above. To ensure
specificity of staining, we performed peptide competitions with the
phosphopeptide immunogen, the corresponding unphosphorylated peptide,
and the erbB2 NPXpY peptide. Double staining with a monoclonal antibody
to calbindin (Sigma) was done to facilitate identification of
hippocampal structures.
Ligation
Adult male rats (Sprague Dawley; 230-300 gm) were anesthetized
with Nembutal, and one of their sciatic nerves was exposed. The nerve
was ligated ~2 cm proximal to the gastrocnemius muscle. Two ligatures
were made adjacent to each other with 6-0 silk. The animals were
allowed to recover and were perfused 24 hr after ligation, as described
above.
Protein lysates
NIH3T3 cells stably transfected with rat TrkA, rat TrkB, or
porcine TrkC (Kaplan et al., 1991 ; Lamballe et al., 1991 ; Soppet et
al., 1991 ) and PC12 cells that overexpress TrkA (Hempstead et al.,
1992 ) were a gift of Dr. David Kaplan. The Trk 3T3 cells were grown in
DMEM with 10% bovine calf serum, penicillin/streptomycin, glutamine,
and 200 µg/ml Geneticin (G418). TrkPC12 cells were grown in the same
media with 5% horse serum. TrkPC12 cells and TrkB 3T3 cells were
changed to serum-free media 1 hr before stimulation by the addition of
NGF or BDNF (50 ng/ml) for 5 min. Cells were harvested in lysis buffer
(20 mM Tris, pH 8, 137 mM NaCl, 1% NP-40, 10%
glycerol, 50 mM NaF, 10 mM NaPPi, 1 mM PMSF, 10 µg/ml aprotinin, 20 µM
leupeptin, 2 mM Na orthovanadate, and 1 mM
ZnCl), mixed for 15 min at 4°C, and cleared by centrifugation.
Sciatic nerves were harvested from adult male rats (Sprague Dawley;
225-300 gm) anesthetized with Nembutal. Nerves were frozen rapidly in
liquid nitrogen and stored at 80°C. For each sample, three whole
nerves or eight nerve segments were pooled. Sciatic nerve extracts were
made by mincing the nerve segments on dry ice and homogenizing them in
a ground glass Dounce in lysis buffer. The extracts were incubated at
4°C for 15 min and cleared by centrifugation. Protein concentration
in extracts was measured by Bio-Rad Protein Assay (Bio-Rad, Melville,
NY). Extracts were stored at 80°C for up to 1 month before use.
Immunoprecipitation and immunoblot analysis
Extracts were immunoprecipitated with either anti-Trk or
anti-pY490 or with no antibody. Sciatic nerve extracts (10-15 mg) and
TrkB 3T3 cell extracts (0.5-1 mg) were immunoprecipitated with
anti-Trk at a 1:100 dilution or with anti-pY490 at a 1:50-1:100 dilution. In competition experiments 100 nM peptide was
preincubated with the pY490 antibody for 30 min at room temperature,
and 100 nM peptide was added to the extracts. Extracts and
antibody were incubated for 2 hr at 4°C. Protein A-Sepharose beads
(50 ml) (Pharmacia Biotech, Uppsala, Sweden) in lysis buffer,
preincubated with 10% BSA, were added to the extracts and incubated
for 1 hr at 4°C. The beads were washed three times with lysis buffer,
twice with 1 M LiCl in 20 mM Tris, pH 7, and
twice with 20 mM Tris, pH 7. Washed beads were resuspended
in 2× reducing sample buffer and boiled for 5 min before being
size-fractionated on a 7.5% SDS-polyacrylamide gel. The gels were
transferred to Immobilon P membranes (Millipore, Bedford, MA), and the
blots were blocked in Blotto (5% nonfat dry milk in TBS) overnight at
4°C and then incubated overnight at 4°C with anti-pY490 (1:500),
anti-Trk (1:2000), or anti-TrkB (1:1000) in Blotto. The blots were
washed in Tris-buffered saline-Tween and incubated with a horseradish
peroxidase-labeled goat anti-rabbit IgG (Bio-Rad), followed by
visualization with enhanced chemiluminescence substrate (Amersham,
Arlington Heights, IL). Alternatively, blots were incubated with
anti-phosphotyrosine (4G10) for 1 hr at room temperature, followed by a
horseradish peroxidase-labeled goat anti-mouse IgG (Bio-Rad), followed
by enhanced chemiluminescence.
BDNF injections
Sciatic nerves of anesthetized adult male rats were exposed at
the gastrocnemius muscle. Recombinant human BDNF (Amgen) or cytochrome
C (Sigma) suspended in PBS was injected into the gastrocnemius muscle
of separate rats at a dose of 5 µg/gm rat, using a Hamilton syringe
(~75-100 µl/muscle). In cut nerve experiments, sciatic nerves were
cut near the gastrocnemius muscle before injection. At 10, 30, or 60 min after injection, sciatic nerves were harvested in three segments.
One segment extended from 1 to 3 cm from the injection site (~0.25 to
2.25 cm from the muscle belly). Two additional segments were taken from
3 to 5 cm and from 5 to 7 cm from the injection site. Samples were
quick-frozen in liquid nitrogen and processed as described above.
In vitro kinase assay
Sciatic nerve extracts and TrkPC12 cells were
immunoprecipitated with anti-Trk. For peptide competition experiments,
the Trk antibody was incubated with 5 µM peptide
immunogen. Immunoprecipitates were washed once with lysis buffer, twice
with 1 M LiCl in 20 mM Tris, and once in kinase
buffer (10 mM Tris, pH 7.4, and 10 mM
MnCl2). The immunoprecipitates were incubated with
~20 µCi -32P-ATP in 30 µl of kinase buffer for 15 min at room temperature, washed twice with cold PBS, and
size-fractionated on a 7.5% SDS-polyacrylamide gel. For Trk kinase
inhibition, 200 nM K252a (Kamiya Biomedical, Thousand Oaks,
CA) was included in the kinase buffer. The gel was dried, and the bands
were visualized with a PhosphoImager (Molecular Dynamics, Sunnyvale,
CA).
Shc association
Sciatic nerve extracts were precleared with Protein A-Sepharose
beads, immunoprecipitated with anti-Shc, and washed twice with lysis
buffer and once with 20 mM Tris. Then immunoprecipitated proteins were size-fractionated and immunoblotted with anti-pY490 as
described above.
Quantitation
TrkB proteins from pY490 immunoprecipitates were electrophoresed
and immunoblotted with anti-phosphotyrosine or anti-TrkB. Films of the
protein bands visualized by enhanced chemiluminescence were quantitated
on an LKB Ultroscan II Enhanced Laser Densitometer. Three exposures
from each experiment were scanned to ensure that quantitation was done
in a linear range. The ratio between the BDNF-injected rats and
cytochrome C-injected rats within each experiment was calculated for
each protein band. The quantitative data from five or six independent
experiments were analyzed. p values were calculated by using
nonparametric statistics (one sample sign test for comparison, with an
expected ratio of 1.0).
RESULTS
Antibody pY490 detects Trks phosphorylated at the Shc
binding site
To determine where and when Trk receptors are activated in neurons
in vivo, we needed an immunochemical probe that could
discriminate activated and inactivated receptor isoforms. In previous
studies we described an antibody, pY490, directed against the
phosphorylated epitope of an NPXY motif that serves as a Shc binding
site in the neurotrophin receptors (Segal et al., 1996 ). To validate
this antibody as an immunohistochemical reagent, we used NIH3T3 cells that had been transfected with the receptors for NGF, BDNF, or NT3
(TrkA, TrkB, or TrkC, respectively) (Kaplan et al., 1991 ; Lamballe et
al., 1991 ; Soppet et al., 1991 ). As shown in Figure 1, no pY490 immunostaining is observed in
untransfected NIH3T3 cells. Control cells stimulated with vehicle alone
show faint immunostaining, which reflects the fact that Trk 3T3 cells
have a low level of constitutive receptor phosphorylation (Kaplan et al., 1991 ). Robust pY490 immunostaining is evident in these 3T3 cells
after stimulation with the appropriate neurotrophin. Immunostaining is
localized primarily to the plasma membrane of the cells, although occasionally staining is most intense in the vicinity of the nucleus. Peptide competition experiments were done to verify the specificity of
the staining (Fig. 1). Immunostaining was abolished by preincubation of
the antibody with its phosphopeptide immunogen. Preincubation of the
antibody with the unphosphorylated peptide or a phosphopeptide corresponding to the NPXpY motif of the erbB2 receptor did not abolish
the staining.
Fig. 1.
Top. Anti-pY490 detects activated TrkA,
TrkB, and TrkC. TrkA-, TrkB-, and TrkC-expressing NIH3T3 cells were
stimulated with neurotrophins and immunostained with the pY490
antibody, followed by avidin-biotin-HRP and DAB. TrkA, TrkB, and TrkC
3T3 cells stimulated with neurotrophin show increased pY490
immunostaining (+), as compared with control cells stimulated with
vehicle alone ( ). Immunostaining is abolished by preincubation of the
antibody with its phosphopeptide immunogen
(phosphopeptide). Preincubation of the antibody
with the corresponding unphosphorylated peptide (peptide) or a phosphopeptide corresponding to
the NPXY motif of the erbB2 receptor (erbB2
phosphopeptide) does not abolish the staining. No staining is
observed in untransfected NIH3T3 cells (NIH).
Scale bar, 10 µm.
Fig. 2.
Middle.
Trk receptors are activated in mature sciatic nerve. Longitudinal
sections of adult rat sciatic nerve were stained with anti-pY490,
followed by avidin-biotin-HRP and DAB. Robust immunostaining is
apparent in sections of nerve stained with anti-pY490 alone
(A). Immunostaining is abolished by preincubation of the antibody with its phosphopeptide immunogen
(C). Preincubation of the antibody with the
corresponding unphosphorylated peptide (B) or a
phosphopeptide corresponding to the NPXY motif of the erbB2 receptor
(D) does not abolish the staining. Scale bar, 10 µm.
Fig. 3.
Bottom. Activated Trk
receptors are present along the length of sciatic nerve axons.
Longitudinal sections from sequential segments along an adult rat
sciatic nerve were immunostained with anti-pY490 and visualized with
avidin-biotin-HRP and DAB. The diagram illustrates the approximate
location of segments along the nerve. Representative pictures from each
segment are shown. Immunostaining is evident in a subset of the axons
in each segment. The staining in each segment is indistinguishable.
Scale bar, 10 µm.
[View Larger Version of this Image (88K GIF file)]
The sensitivity of the pY490 antibody for detecting physiological
changes in Trk phosphorylation has been tested in vivo. Hippocampal staining with anti-pY490 is reduced in BDNF / animals, as compared with wild-type controls (data not shown), whereas seizures
increase pY490 immunostaining (J. Park and C. Stiles, unpublished
observations). The pY490 antibody therefore can be used to detect
activated TrkA, TrkB, and TrkC in immunocytochemistry as well as in
biochemical analysis.
Phospho-Trk antibodies reveal activated Trks in rat
sciatic nerve
As shown in Figure 2, activated Trk
receptors can be found in the adult rat sciatic nerve. Figure
2A shows longitudinal sections of adult rat sciatic
nerve immunostained with anti-pY490. Peptide competition experiments
(Fig. 2B-D) were done to establish that the antibody
specifically recognizes phosphorylated Trks in the nerve.
Immunostaining is abolished by preincubation of the antibody with its
phosphopeptide immunogen, but not by preincubation of the antibody with
the corresponding unphosphorylated peptide or a phosphopeptide
corresponding to the NPXpY motif of the erbB2 receptor. The presence of
activated receptors in sciatic nerve, as assayed with anti-pY490,
indicates that neurotrophins are active in the adult peripheral nervous
system.
Activated Trks are present along the length of axons
Each of the models of neurotrophin signaling outlined above
predicts a particular distribution of activated Trks within axons. To
distinguish among the diverse models, we investigated the localization of activated Trks within the sciatic nerve. To determine how activated Trk receptors are distributed in the 6-7 cm of length between the cell
bodies and the nerve terminals of the sciatic nerve, longitudinal
sections from five sequential 1 cm segments were immunostained with
anti-pY490. Representative pictures from each segment are shown in
Figure 3. Activated Trks are evident in
axons in panels A-E, suggesting that activated Trks are
distributed uniformly within axons along the entire length of the
sciatic nerve. A similar percentage of axons is stained in each
segment. The uniform distribution of activated Trks along the length of axons is consistent with a model of retrograde signaling wherein Trk
functions as a retrograde signal carrier.
The appearance of pY490 immunostaining in Figures 2 and 3 suggests that
activated receptors are found within axons. To confirm this impression,
we costained sections of sciatic nerve with anti-pY490 and an antibody
to acetylated -tubulin, a marker of axons (Chitnis and Kuwada,
1990 ). Figure 4A shows
that activated Trks are present in axons of the sciatic nerve. Further
double-staining experiments were done with antibodies to -tubulin,
neurofilament proteins, and S-100 (data not shown). These costaining
experiments confirm that activated Trks are confined to axons and are
not present in Schwann cells or perineurial fibroblasts.
Fig. 4.
Activated Trk receptors are confined to axons in
the sciatic nerve and accumulate distal to a ligation.
A, Longitudinal sections of adult rat sciatic nerve were
immunostained with anti-acetylated -tubulin (acetylated
tubulin) and anti-pY490 (pY490), as
described, and viewed with fluorescence optics. Double labeling is
shown in sections viewed with both fluorescein and rhodamine filters (double). All axons in the sciatic nerve are labeled by
the acetylated tubulin antibody. In contrast, fewer axons are stained
by anti-pY490. Colocalization is apparent as yellow in
the double panels, demonstrating that pY490 labels only a subset of
axons. Another field viewed at higher magnification (second
row) shows that the anti-pY490 staining colocalizes with the
acetylated tubulin staining, verifying that the pY490 immunostaining is
present in axons of the sciatic nerve. Scale bars: First
row, 50 µm; second row, 25 µm.
B, The sciatic nerve of an adult rat was ligated ~2 cm
from the gastrocnemius muscle to interrupt vesicular transport. At 24 hr after ligation the nerve was harvested, and longitudinal sections of
the nerve were immunostained with an antibody to the coated vesicle
protein, clathrin and anti-pY490. The portion of nerve distal to the
ligation site is shown with the ligation site to the
right. Clathrin immunostaining shows accumulation of
clathrin in axons on the distal side of the ligation
(clathrin). Phosphorylated Trks, as shown by pY490 immunostaining, also accumulate on the distal side of the ligation (pY490). Costaining shows that phosphorylated
Trks colocalize with clathrin (double). Scale bar, 50 µm.
[View Larger Version of this Image (110K GIF file)]
These experiments also demonstrate that activated Trks are not found in
all axons but are restricted to a subset of axons in the nerve. All of
the pY490 immunoreactive axons also stained with the antibody to
acetylated tubulin. However, only 10-40% of the axons in the nerve
are stained with the pY490 antibody. The subset of axons that have
detectable levels of activated Trk within them does not represent an
obvious class of axons in the nerve (e.g., unmyelinated vs myelinated).
Although virtually all neurons that travel in the sciatic nerve express
one of the Trk species, it is important to note that we are visualizing
phosphorylated Trks within axons at one instant in time. Therefore, the
subset of axons that have detectable pY490 immunostaining may reflect transient phosphorylation of Trks rather than the segregation of
activated Trks within one type of axon.
Activated Trks accumulate distal to a ligation
To determine whether phosphorylated Trk receptors in the axons are
involved in retrograde signaling, we interrupted transport through the
sciatic nerve by ligation. We then immunostained the nerves 24 hr after
ligation (Fig. 4B). Activated Trk receptors, detected
with anti-pY490, accumulate in axons on the distal side of the
ligation, but not on the proximal side, indicating that phosphorylated
Trks are moving from the synapse toward the cell body. Nerve ligation
interrupts vesicular transport and results in an accumulation of
vesicles at the ligation site but also might interrupt nonvesicular
movement. Clathrin, a protein component of coated vesicles, accumulates
in axons on the distal side of the ligation and colocalizes with
phosphorylated Trks (Fig. 4B). These results suggest
that phosphorylated Trk receptors are traveling by retrograde vesicular
transport.
Anti-pY 490 recognizes activated Trks in nerve extracts
To verify that the immunohistochemical images displayed by pY490
in rat sciatic nerve correspond to activated Trks, we performed biochemical analyses. These verified the nature of anti-pY490 immunoreactive proteins and provided a quantitative method for analyzing responses to exogenous neurotrophin. In these and subsequent biochemical analyses we chose to focus on activation of TrkB, because
recombinant neurotrophins can be administered readily as a bolus
injection to gastrocnemius muscle, and the BDNF receptor TrkB is the
most abundant receptor at motor nerve terminals.
Sciatic nerve extracts were immunoprecipitated with a pan-Trk antibody
that recognizes all full-length Trk species. These immunoprecipitates
were size-fractionated and then immunoblotted with anti-pY490,
anti-Trk, and anti-TrkB (Fig.
5A). An artifactual band at
165 kDa is seen in all immunoprecipitates of sciatic nerve and
represents a protein that is brought down by protein A-Sepharose beads.
This band is variably recognized by anti-immunoglobulin secondary
antibodies, as shown in the no antibody lanes. Anti-pY490 recognizes a
diffuse band at 140-150 kDa and a single band with molecular mass of
180 kDa. The broad band at 140-150 kDa also is recognized by the
pan-Trk antibody. The TrkB antibody recognizes a subset of protein
within the broad band. Thus anti-pY490 recognizes activated TrkB from
sciatic nerve lysates and also detects activated TrkA and/or TrkC
immunoprecipitated by the pan-Trk antibody.
Fig. 5.
Anti-pY490 recognizes two forms of phosphorylated
TrkB in the adult rat sciatic nerve. A, Extracts of
adult rat sciatic nerve were immunoprecipitated with anti-Trk and
immunoblotted with anti-pY490 (pY490), anti-Trk
(pan Trk), or a TrkB-specific antibody
(TrkB). Incubation of the samples with Protein
A-Sepharose beads alone resulted in the binding of a nonspecific
protein at ~165 kDa (no ab). Anti-pY490 recognizes a
diffuse band at 140-150 kDa as well as a distinct band at 180 kDa in
the Trk immunoprecipitates. The broad band is recognized by anti-Trk,
whereas anti-TrkB recognizes a subset within this band. The 180 kDa
band is weakly recognized by anti-TrkB. B, Nerve
extracts were immunoprecipitated by the pY490 antibody alone or
preincubated with peptide and immunoblotted with anti-phosphotyrosine.
Two proteins of 145 and 180 kDa are recognized by anti-phosphotyrosine
(pY) in extracts immunoprecipitated with
anti-pY490 alone (no peptide). Preincubation of the
pY490 antibody with its phosphopeptide immunogen
(peptide-P), but not preincubation of the
antibody with the corresponding unphosphorylated peptide
(peptide-OH), prevented
immunoprecipitation of these two bands. C, Extracts of
sciatic nerve (nerve) and unstimulated ( ) or
BDNF-stimulated (+) TrkB 3T3 cells were immunoprecipitated with pY490
antibody and immunoblotted with anti-pY490
(pY490), anti-TrkB (TrkB), and
anti-phosphotyrosine (pY). Both the 145 and 180 kDa bands are immunoprecipitated from nerve extracts with the
pY490 antibody. The TrkB antibody recognizes the 145 kDa band and
weakly recognizes the 180 kDa band. Both bands are recognized by
anti-phosphotyrosine.
[View Larger Version of this Image (48K GIF file)]
Anti-pY490 also recognizes a 180 kDa protein within pan-Trk
immunoprecipitates. This higher molecular weight species reacts weakly
with the anti-TrkB antibody used here as well as a different antibody
specific for TrkB (data not shown). On the basis of these results, the
higher molecular weight protein may be a TrkB isoform analogous to
higher molecular weight forms of TrkA reported in rat sciatic nerve
(Ehlers et al., 1995 ).
In Figure 5C we show that anti-pY490 can be used to
immunoprecipitate selectively the activated Trks from sciatic nerve
lysates. Both the 145 and 180 kDa proteins are immunoprecipitated by
pY490 antibody alone and are recognized by antibodies to TrkB or
phosphotyrosine. These data confirm that anti-pY490 recognizes
phosphorylated Trk receptors in sciatic nerve, including a predominant
TrkB species of 145 kDa and a highly phosphorylated 180 kDa form of
TrkB. To establish the specificity of pY490 antibody as an
immunoprecipitating agent, we preincubated the antibody with the
phosphorylated immunogen or the corresponding unphosphorylated peptide
(Fig. 5B). As shown, the phosphopeptide preferentially
inhibits immunoprecipitation of all activated Trk isoforms.
TrkB within axons responds to target-derived factors
Activated Trk receptors within the sciatic nerve could be
regulated by neurotrophins synthesized by target cells, Schwann cells,
and/or neurons. To determine whether the Trk receptors in sciatic nerve
axons are activated by target-derived factors, we monitored the
response to exogenous neurotrophin. A bolus of BDNF (5 µg/gm animal
weight) was injected into the gastrocnemius muscle of adult rats. This
large muscle is a target of sciatic nerve motor and sensory neurons.
Control animals were injected with an equal amount of cytochrome C. At
10, 30, and 60 min after injection, we harvested the nerves in three
segments. The distal segment begins 1 cm from the injection site and
extends to 3 cm from this site, the middle segment extends from 3 to 5 cm from the injection, and the proximal segment extends from 5 to 7 cm from injection. Protein extracts of these segments were
immunoprecipitated with anti-pY490 and immunoblotted with
anti-phosphotyrosine and with anti-TrkB. For each experiment, sciatic
nerves from eight BDNF-injected and eight cytochrome-C-injected control
rats were harvested and pooled.
At 10 min after BDNF injection, there is an increase in the amount of
activated TrkB in extracts of the distal nerve segments (Fig.
6, Table
1). Using anti-phosphotyrosine or
anti-TrkB to blot the pY490 immunoprecipitates, we detected a twofold
increase in the 145 kDa form and approximately a fivefold increase in
the 180 kDa form (Table 1). Quantitative analysis of seven independent experiments confirmed that the increases in both protein species are
reproducible and statistically significant.
Fig. 6.
TrkB receptors in sciatic nerve respond to
target-derived BDNF. A, Cytochrome C ( ) or BDNF (+)
was injected into the gastrocnemius muscle of adult rats
(intact). In cut nerve experiments (cut), sciatic nerves were cut near the gastrocnemius muscle before injection. Distal segments of sciatic nerves (1-3 cm from the injection site) were harvested 10 min after injection. Nerve extracts were
immunoprecipitated with anti-pY490 and immunoblotted with
anti-phosphotyrosine (pY) or anti-TrkB
(TrkB). A nonspecific band is present in the blots at
~165 kDa. Both the 145 and 180 kDa TrkB bands (arrows)
are increased after BDNF injection (intact). When the
nerve is cut before injection, no increase in these bands is observed
with BDNF injection (cut). B, Cytochrome
C ( ) or BDNF (+) was injected into the gastrocnemius muscle of adult
rats. Distal segments of sciatic nerves from these animals were
harvested 10 and 60 min after injection. Nerve extracts and
unstimulated ( ) or BDNF-stimulated (+) TrkB 3T3 cells were
immunoprecipitated with anti-pY490 and immunoblotted with
anti-phosphotyrosine (P-tyr). There is an increase in both 145 and 180 kDa Trk bands within 10 min after BDNF injection. By 60 min after
injection, the levels of Trk are equal to cytochrome C control
( ).
[View Larger Version of this Image (44K GIF file)]
Table 1.
BDNF applied at nerve endings causes an induction of TrkB
phosphorylation in sciatic nerve axons
| TrkB species |
Time after injection (minutes) |
Fold induction:
TrkB phosphorylation of BDNF injected/control (mean ± SE) |
|
| 145
kDa |
10 |
2.0 ± 0.4* |
|
30 |
2.3
± 0.6 |
|
60 |
1.1 ± 0.2 |
| 180 kDa |
10 |
5.3
± 1.7* |
|
|
BDNF or cytochrome C (control) was injected into the
gastrocnemius muscle of adult rats, and the ipsilateral sciatic nerves were harvested 10, 30, or 60 min after injection. Sciatic extracts of
eight animals were pooled for each condition and were
immunoprecipitated with anti-pY490, immunoblotted with
anti-phosphotyrosine, and visualized by enhanced chemiluminescence. The
ratio between TrkB phosphorylation in BDNF-injected and control nerves
within each experiment was calculated. Values shown represent the mean
induction seen in eight experiments (145 kDa, 10 min time point), seven experiments (180 kDa, 10 min), five experiments (145 kDa, 30 min), or
three experiments (145 kDa, 60 min).
*
Value is significantly greater
than 1.0 (p < 0.05).
|
|
To ensure that the neurotrophin injected into the muscle remains
localized within this target, we monitored the dispersion of tagged
BDNF after injection. We injected biotinylated BDNF into the muscle,
harvested both the muscle and the nerve after 10 min, and assayed each
for the presence of biotinylated BDNF. Biotinylated BDNF is not
detected in the nerve, but it is detected easily in muscle extract
(data not shown). These data indicate that the increase in
phosphorylated TrkB observed in sciatic nerve is a remote response to
neurotrophin in the muscle target.
To confirm that the observed signal is traveling through the axon
rather than extra-axonally, we cut the nerve at the usual site of
excision (~1 cm from the injection site) before injection and then
repeated the experiment. No increase in Trk activation was observed
when the continuity of the nerve was interrupted (Fig.
6A). Collectively, these data indicate that the
activation state of Trk receptors within the sciatic nerve is
regulated, at least in part, by target-derived neurotrophins, and the
response to target-derived factors travels through the nerve
itself.
In these biochemical experiments we can analyze specifically the
response of TrkB receptors to BDNF. Using immunohistochemistry, we
cannot distinguish the identity of the activated Trk receptors. In
immunohistochemical experiments with anti-pY490, we did not detect any
increase in the number of axons containing activated Trk receptors in
distal segments of BDNF injected nerves, as compared with cytochrome
C-injected nerves and with control nerves (26% in control and in
BDNF-injected). This result may indicate that the increase in TrkB
phosphorylation after BDNF injections reflects an increase in the
number of activated receptors per axon rather than an increase in the
number of axons with activated receptors.
BDNF rapidly activates distant TrkB receptors
A surprising element of axonal TrkB activation in response to
target-applied BDNF is that the increased activation in the distal
segments is apparent within 10 min and remains apparent at 30 min after
injection. Furthermore, Trk activation returns to the basal,
unstimulated level by 60 min after the injection (Fig.
6B, Table 1). The return to baseline is likely to
reflect further propagation of the signal toward the cell body and
receptor downregulation in response to the large bolus of neurotrophin. Thus, the response has traveled 1 cm from the injection site within 10 min and 3 cm from the injection site within 60 min. This corresponds to
a rate of signal propagation of 8-16 µm/sec, a rate faster than
conventional retrograde vesicular transport, previously reported as
2-5 µm/sec (Richardson and Riopelle, 1984 ; Sheetz et al., 1989 ; Vallee and Bloom, 1991 ). As expected, on the basis of the
immunohistochemistry (Fig. 3) anti-pY490 also immunoprecipitated
activated Trks from the middle and proximal segments of control and
BDNF injected nerves. Thus far we have not detected any significant
increase in Trk phosphorylation in these nerve segments at 10, 30, or
60 min after injection.
Axonal Trk has catalytic and signal-generating activities
During neurotrophin signaling Trk receptors act as enzymes that
catalyze protein phosphorylation, and they also act as a platform for
the assembly of a multimeric signal-generating complex (Segal and
Greenberg, 1996 ). To determine whether Trks within axons of sciatic
nerve are enzymatically active, we performed an in vitro autophosphorylation assay on whole-nerve extracts. In anti-Trk immunoprecipitates we detect autophosphorylation of a broad band at 145 kDa, which corresponds in molecular mass to the major isoforms of TrkA,
TrkB, and TrkC (Fig. 7A). The
specificity of these kinase assays for detecting Trk kinase activity
was assessed in two ways. Peptide competitions showed that this band is
immunoprecipitated specifically by the anti-Trk antibody (Fig.
7A). Furthermore, autophosphorylation was prevented by the
Trk kinase inhibitor K252a (Fig. 7B).
Fig. 7.
Target-derived neurotrophin increases the
catalytic activity of axonal Trk receptors. Extracts of normal whole
sciatic nerves and TrkPC12 cells, either stimulated (+) or unstimulated
( ) with NGF, were immunoprecipitated with anti-Trk or in the presence of peptide immunogen. An in vitro autophosphorylation
assay was performed on the Trk immunoprecipitates. The
immunoprecipitates were incubated with -32P-ATP. The
arrow indicates a broad band at 145 kDa, corresponding to autophosphorylation of Trk isoforms in the nerve. TrkA
autophosphorylation is increased in TrkPC12 cells stimulated with NGF
(+). The identities of the bands in these immunoprecipitates were
confirmed by the peptide competition. B, Extracts of
distal segments of cytochrome C-injected ( ) or BDNF-injected (+)
nerves and TrkPC12 cells, either control ( ) or NGF-stimulated (+),
were immunoprecipitated with anti-Trk. Note that the amount of protein
used in each immunoprecipitation in this experiment is approximately
one-half of that in A. The immunoprecipitates were
incubated with -32P-ATP alone or in the presence of
K252a (+K252a), a Trk kinase inhibitor. The
arrow indicates the 145 kDa species of Trk in the nerve.
Trk autophosphorylation is increased in nerves injected with BDNF and
in TrkPC12 cells stimulated with NGF. No kinase activity is apparent in
extracts incubated with K252a. C, Extracts of normal rat
sciatic nerves and TrkB 3T3 cells stimulated with BDNF (+) or
unstimulated ( ) were immunoprecipitated with anti-Shc and
immunoblotted with anti-pY490. Precipitation with Protein A-Sepharose
beads alone (no Ab) resulted in the binding of a
nonspecific band at ~165 kDa. A phosphorylated Trk band at 145 kDa is
detected in the Shc immunoprecipitates, verifying that phospho-Trk is
associated with Shc in nerve extracts.
[View Larger Version of this Image (44K GIF file)]
To determine whether axonal Trk catalytic activity is regulated
by target derived neurotrophins, we repeated this experiment on distal
segments of sciatic nerve from rats that had been injected with BDNF or
cytochrome C, as described above. The 145 kDa Trk kinase band can be
seen in extracts from unstimulated distal segments, although we used
approximately one-half the amount of protein used in whole-nerve
experiments. At 10 min after BDNF injection, there is a fourfold
increase in autophosphorylation of the 145 kDa Trk proteins within the
distal nerve segment (Fig. 7B). These enzymatic studies
provide further evidence that axonal Trks are regulated rapidly by
target-derived neurotrophins.
To determine whether axonal Trks also function as platforms for the
assembly of signal-generating molecules, we looked at receptor
association with the crucial signal transduction molecule, Shc. Sciatic
nerve extracts were immunoprecipitated with an antibody to Shc and
immunoblotted with anti-pY490. Figure 7C shows that activated Trk is associated with Shc in the sciatic nerve. Taken together, our data indicate that, in axons, Trks are phosphorylated at
the critical Shc recognition site, are catalytically active kinases,
and are associated with Shc. These attributes are regulated by
neurotrophin stimulation at the nerve terminals.
DISCUSSION
Functions of neurotrophins in the mature nervous system
Target-derived neurotrophins initiate a retrograde signal that is
required for the survival of neurons in the developing peripheral nervous system. However, it has not been clear whether these molecules exert remote effects in the mature nervous system. Using a positionally specific phospho-Trk antibody, we have visualized Trk receptors phosphorylated at the Shc binding site in adult sciatic nerve axons.
Tyrosine phosphorylation at this site is a particularly good indicator
of the ability of Trk to act as a platform for assembly and activation
of signaling molecules (Obermeier et al., 1994 ; Stephens et al., 1994 ).
Furthermore, axonal Trk receptors are catalytically active and are
associated with the signal-generating molecule Shc. The presence of
activated receptors in sciatic nerve axons and the demonstration that
the receptors are activated in response to neurotrophins applied at
distant nerve terminals indicate that target-derived factors continue
to exert remote effects on presynaptic neurons throughout life.
What are the functions of target-derived factors in mature neurons?
Studies by Acheson et al. demonstrate that the survival of adult
sensory neurons is dependent on autocrine neurotrophins rather than on
factors produced by the targets (Acheson et al., 1995 ). However,
focally applied neurotrophins can modulate transcriptional changes in
response to nerve injury (Friedman et al., 1995 ). This raises the
possibility that target-derived factors in the adult peripheral nervous
system initiate retrograde signals necessary for nerve and synapse
maintenance and repair. This is supported by data from the peripheral
nervous system and CNS. In the peripheral nervous system NGF increases
the caliber of axonal fibers (Gold et al., 1991 ), whereas NGF
antibodies inhibit the sprouting of adult DRG neurons (Diamond et al.,
1992a ). In the CNS long-term potentiation is impaired in mice with
targeted gene deletions of BDNF, and this defect is rescued by
exogenous neurotrophin (Kang and Shuman, 1995 ; Korte et al., 1995 ;
Figurov et al., 1996 ; Patterson et al., 1996 ).
What carries the retrograde signal?
Although the functions of target-derived neurotrophins in the
developing and mature nervous system may differ, in both cases a
neurotrophin-initiated signal must be propagated from the nerve terminal to the cell body. Three models for retrograde signaling have
been proposed and are outlined above (Hendry and Crouch, 1993 ;
Campenot, 1994 ). According to the first model, neurotrophin itself is
the agent responsible for retrograde signaling. Although neurotrophins
in vivo are internalized specifically and transported retrogradely by responsive neurons, arriving intact at the neuronal cell body (Hendry, 1975 ; Johnson, 1978 ; DiStefano et al., 1992 ), intracellular injection of neurotrophins fails to elicit a response, and injected neurotrophin antibodies fail to inhibit a response (Heumann et al., 1981 ; Rohrer et al., 1982 ), casting doubt on the
hypothesis that internalized neurotrophin is the signal carrier. Our
data demonstrating that Trk receptors are activated throughout the axon
provide further evidence against this model.
The distribution of activated Trk receptors within the sciatic nerve
also provides evidence against the second model of signaling, because
our data show that activated Trks are all along the axon and not only
at the nerve terminal. Thus downstream signaling molecules, such as Ras
or MAP Kinase, cannot be the only retrograde signal carriers.
Our studies support the hypothesis that Trk receptors function as
retrograde signal carriers, as outlined in the third model. In response
to neurotrophins delivered to the muscle target, there are rapid
increases in phosphorylation state and catalytic activity of axonal Trk
receptors located at least 1 cm from the nerve terminal. This response
involves an intracellular signal that travels through the nerve,
because BDNF-dependent Trk phosphorylation is prevented by nerve
transection. Similarly, Ehlers et al. have demonstrated that
target-derived NGF can cause, and antibodies to NGF can inhibit, the
phosphorylation of TrkA receptors in a ligated nerve (Ehlers et al.,
1995 ). Thus phosphorylation state and catalytic activity of Trk
receptors within sciatic nerve axons reflect the level of neurotrophin
at the nerve terminal. Because the phosphorylated Trk receptors within
sciatic nerve are catalytically active and are associated with
signal-generating molecules, they are ideal agents for propagating a
biological response. Are these signal-generating particles associated
with neurotrophins? No one has observed a population of neurotrophin
that moves within the axon as fast as Trk phosphorylation (Fig. 6,
Table 1). Thus, if ligand is associated with the signal-generating
complex, it can amount to no more than a small fraction of the total
transported neurotrophin within the axon.
The theory that membrane-bound receptors at the nerve terminals and
internalized receptors within the axon, whether alone or as part of
ligand-receptor complexes, are engaged in signal transduction all
along the length of the axon is consistent with data from Campenot that
NGF promotes axonal stability only between the site of NGF application
and the cell body (Campenot, 1994 ). These en route retrograde effects
could be explained by activated receptors that are distributed
throughout the axon and are engaged in signal transduction.
Surprisingly, although activated receptors are detected all along the
length of the nerve, thus far we have found a BDNF-induced increase in
TrkB activation within a segment of sciatic nerve that extends from 1 to 3 cm from the injection site and not within the segments of the
nerve farther from the injection site. This may reflect technical
constraints, in that a smaller proportion of axons in the proximal
nerve projects to the gastrocnemius muscle and so any increase may be
below the level of detection. Another possibility is that we have not
analyzed Trk phosphorylation in the middle and proximal segments at the
critical time period. Alternatively, Trk receptors could be signal
carriers only in the initial axonal segments. In the future it will be
critical to link the neurotrophin-induced increase in axonal Trk
phosphorylation to somatic responses to determine whether activated
Trks are the initial or the sole signal carriers.
The mechanism of rapid signal propagation
Delineating the signal carrier is a first step toward elucidating
the mechanism by which a retrograde signal is initiated and propagated
through axons. Further studies will be needed to show definitively that
phosphorylated Trk is associated with vesicles in neuronal axons, an
association previously demonstrated in PC12 cells (Grimes et al.,
1996 ). However, our data showing that phosphorylated Trk receptors
accumulate distal to a ligation are consistent with a model that
retrograde transport of vesicle-associated activated receptor
propagates the signal.
The surprising finding is the rapidity of the response, which is not
consistent with the speed of conventional retrograde vesicular
transport. As shown (Fig. 6, Table 1), 10 min after injection of BDNF
into the gastrocnemius muscle, we detect an increased level of
activated TrkB in a segment of nerve that begins at 1 cm and extends to
3 cm from the injection site. Similarly, 10 min after neurotrophin
injection we detect an increase in Trk catalytic activity in this nerve
segment (Fig. 7). Thus the signal, as assessed by two independent
criteria, has traveled 16 µm/sec into this initial nerve segment. If
the subsequent return to basal levels of Trk phosphorylation 60 min
after neurotrophin injection reflects continued retrograde movement of
Trk receptors, then the signal has traveled through the segment at 8 µm/sec. Previous studies on neurotrophin transport in rat sciatic
nerve have shown that in this system neurotrophins are transported to
the cell body at 0.7-2 µm/sec (Richardson and Riopelle, 1984 ), which
is similar to other in vivo and in vitro
measurements of vesicular transport and is lower than the rate of Trk
signal propagation shown here (Richardson and Riopelle, 1984 ; Sheetz et
al., 1989 ; Vallee and Bloom, 1991 ).
Two mechanisms by which activated Trk could propagate a retrograde
signal are consistent with the data shown here. The first possibility
is that Trk receptors are activated at the nerve terminals and then
endocytosed alone or in a complex with ligand. Activated Trks travel
from the nerve terminal by fast retrograde transport. As they move
through the axon, activated Trk receptors remain catalytically active
and continue to initiate signal transduction pathways by interacting
with downstream signaling molecules. At some point, perhaps at the
soma, the downstream effectors convey a signal from the
vesicle-associated receptor to the nucleus.
An alternative hypothesis is that signal propagation in the initial
nerve segment does not reflect the movement of individual molecules of
phosphorylated Trk but, instead, represents a rapid change in
phosphorylation state of Trk molecules that are distributed throughout
the nerve terminal and distal axon. In the future in vitro
model systems (Campenot, 1982 ) will make it possible to determine
whether Trk phosphorylation is propagated biochemically or physically
through the axon and to ascertain the location and mechanism whereby a
retrograde signal is converted from activated receptor to a nuclear
response.
FOOTNOTES
Received April 30, 1997; revised June 26, 1997; accepted July 1, 1997.
This work was supported by National Institutes of Health Grants NS35148
(R.A.S., C.D.S., A.B.) and NS27773 (S.L.P.) and by a Children's
Hospital core Grant (HD18655). A.B. was a postdoctoral fellow of the
Robert Steel Foundation for Pediatric Cancer Research. R.A.S. is a
Robert Ebert Clinical Fellow of the Klingenstein Foundation. We thank
Dr. Andrew Welcher, Amgen Incorporated, for generously providing us
with recombinant BDNF and Drs. David Kaplan (Montréal Neurological Institute) and Thomas Roberts (Dana-Farber Cancer Institute) for the generous gift of antibodies and transfected cell
lines. We thank Abha Chandra, Lori Rua, and Ken Thress for technical
assistance.
In compliance with Harvard Medical School guidelines on possible
conflict of interest, we disclose that one of the authors (C.D.S.) has
consulting relationships with Upstate Biotechnology and Sandoz
Pharmaceuticals.
Correspondence should be addressed to Dr. Rosalind A. Segal, Department
of Neurology, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur,
Boston, MA 02115.
REFERENCES
-
Acheson A,
Conover J,
Fandl J,
DeChiara T,
Russell M,
Thadani A,
Squinto S,
Yancopoulos G,
Lindsay R
(1995)
A BDNF autocrine loop in adult sensory neurons prevents cell death.
Nature
374:450-453[Medline].
-
Barbacid M
(1994)
The Trk family of neurotrophin receptors.
J Neurobiol
25:1386-1403[Web of Science][Medline].
-
Barde YA
(1989)
Trophic factors and neuronal survival.
Neuron
2:1525-1534[Web of Science][Medline].
-
Bothwell M
(1991)
Keeping track of neurotrophin receptors.
Cell
65:915-918[Web of Science][Medline].
-
Campenot RB
(1982)
Development of sympathetic neurons in compartmentalized cultures. I. Local control of neurite growth by nerve growth factor.
Dev Biol
93:1-12[Web of Science][Medline].
-
Campenot RB
(1987)
Local control of neurite sprouting in cultured sympathetic neurons by nerve growth factor.
Brain Res
465:293-301[Medline].
-
Campenot RB
(1994)
NGF and the local control of nerve terminal growth: review.
J Neurobiol
25:599-611[Web of Science][Medline].
-
Chitnis AB,
Kuwada JY
(1990)
Axonogenesis in the brain of zebrafish embryos.
J Neurosci
10:1892-1905[Abstract].
-
Deckwerth TL,
Johnson EJ
(1993)
Neurotrophic factor deprivation-induced death.
Ann NY Acad Sci
679:121-131[Web of Science][Medline].
-
Diamond J,
Foerster A,
Holmes M,
Coughlin M
(1992a)
Sensory nerves in adult rats regenerate and restore sensory function to the skin independently of endogenous NGF.
J Neurosci
12:1467-1476[Abstract].
-
Diamond J,
Holmes M,
Coughlin M
(1992b)
Endogenous NGF and nerve impulses regulate the collateral sprouting of sensory axons in the skin of the adult rat.
J Neurosci
12:1454-1466[Abstract].
-
DiStefano PS,
Friedman B,
Radziejewski C,
Alexander C,
Boland P,
Schick CM,
Lindsay RM,
Wiegand SJ
(1992)
The neurotrophins BDNF, NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons.
Neuron
8:983-993[Web of Science][Medline].
-
Druker B,
Mamon H,
Roberts T
(1989)
Oncogenes, growth factors, and signal transduction.
N Engl J Med
321:1383-1391[Web of Science][Medline].
-
Ehlers M,
Kaplan D,
Price D,
Koliatsos V
(1995)
NGF-stimulated retrograde transport of trkA in the mammalian nervous system.
J Cell Biol
130:149-156[Abstract/Free Full Text].
-
Figurov A,
Pozzo-Miller L,
Olafsson P,
Wang T,
Lu B
(1996)
Regulation of synaptic responses to high frequency stimulation and LTP by neurotrophins in the hippocampus.
Nature
381:706-709[Medline].
-
Friedman B,
Kleinfeld D,
Ip N,
Verge V,
Moulton R,
Boland P,
Zlotchenko E,
Lindsay R,
Liu L
(1995)
BDNF and NT4/5 exert neurotrophic influences on injured adult spinal motor neurons.
J Neurosci
15:1044-1056[Abstract].
-
Gold B,
Mobley W,
Matheson S
(1991)
Regulation of axonal caliber, neurofilament content, and nuclear localization in mature sensory neurons by nerve growth factor.
J Neurosci
11:943-955[Abstract].
-
Grimes M,
Zhou J,
Beattie E,
Yuen E,
Hall D,
Valletta J,
Topp K,
LaVail J,
Bunnett N,
Mobley W
(1996)
Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes.
J Neurosci
16:7950-7964[Abstract/Free Full Text].
-
Hempstead BL,
Rabin SJ,
Kaplan L,
Reid S,
Parada LF,
Kaplan DR
(1992)
Overexpression of the trk tyrosine kinase rapidly accelerates nerve growth factor-induced differentiation.
Neuron
9:883-896[Web of Science][Medline].
-
Hendry IA
(1975)
The response of adrenergic neurons to axotomy and nerve growth factor.
Brain Res
94:87-97[Web of Science][Medline].
-
Hendry IA,
Crouch M
(1991)
Retrograde axonal transport of the GTP-binding protein Gi
: a potential neurotrophic intra-axonal messenger.
Neurosci Lett
133:29-32[Web of Science][Medline]. -
Hendry IA,
Crouch M
(1993)
Synergy, retrograde transport, and cell death.
In: Neurotrophic factors (Loughlin S,
Fallon J,
eds), pp 51-88. Boston: Academic.
-
Heumann R,
Schwab M,
Thoenen H
(1981)
A second messenger required for nerve growth factor biological activity?
Nature
292:838-840[Medline].
-
Hosang M,
Shooter EM
(1987)
The internalization of nerve growth factor by high-affinity receptors on pheochromocytoma PC12 cells.
EMBO J
6:1197-1202[Web of Science][Medline].
-
Johanson S,
Crouch M,
Hendry I
(1995)
Retrograde axonal transport of signal transduction proteins in rat sciatic nerve.
Brain Res
690:55-63[Web of Science][Medline].
-
Johnson Jr EM
(1978)
Destruction of the sympathetic nervous system in neonatal rats and hamsters by vinblastine; prevention by concomitant administration of nerve growth factor.
Brain Res
141:105-118[Web of Science][Medline].
-
Johnson Jr EM,
Taniuchi M,
Clark H,
Springer J,
Koh S,
Tayrien M,
Loy R
(1987)
Demonstration of the retrograde transport of nerve growth factor receptor in the peripheral and central nervous system.
J Neurosci
7:923-929[Abstract].
-
Kahle P,
Barker P,
Shooter E,
Hertel C
(1994)
p75 nerve growth factor receptor modulates p140TrkA kinase activity, but not ligand internalization, in PC12 cells.
J Neurosci Res
38:599-606[Web of Science][Medline].
-
Kang H,
Shuman E
(1995)
Neurotrophin-induced modulation of synaptic transmission in the adult hippocampus.
J Physiol (Lond)
89:11-22.
-
Kaplan DR,
Hempstead BL,
Martin-Zanca D,
Chao MV,
Parada LF
(1991)
The trk proto-oncogene product: a signal transducing receptor for nerve growth factor.
Science
252:558-561[Abstract/Free Full Text].
-
Korte M,
Carroll P,
Wolf E,
Brem G,
Thoenen H,
Bonhoeffer T
(1995)
Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor.
Proc Natl Acad Sci USA
92:8856-8860[Abstract/Free Full Text].
-
Lai E,
Clark KL,
Burley SK,
Darnell Jr JE
(1993)
Hepatocyte nuclear factor 3/fork head or "winged helix" proteins: a family of transcription factors of diverse biologic function.
Proc Natl Acad Sci USA
90:10421-10423[Abstract/Free Full Text].
-
Lamballe F,
Klein R,
Barbacid M
(1991)
TrkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin 3.
Cell
66:967-979[Web of Science][Medline].
-
Levi-Montalcini R
(1987)
The nerve growth factor 35 years later.
Science
237:1154-1162[Free Full Text].
-
Levi-Montalcini R,
Angeletti PU
(1968)
Nerve growth factor.
Physiol Rev
48:534-569[Free Full Text].
-
Loy R,
Lachyankar M,
Condon P,
Poluha D,
Ross A
(1994)
Retrograde axonal transport and lesion-induced upregulation of the TrkA high-affinity NGF receptor.
Exp Neurol
130:377-386[Web of Science][Medline].
-
Mehler MF,
Kessler JA
(1994)
Growth factor regulation of neuronal development.
Dev Neurosci
16:180-195[Web of Science][Medline].
-
Obermeier A,
Bradshaw RA,
Seedorf K,
Choidas A,
Schlessinger J,
Ullrich A
(1994)
Neuronal differentiation signals are controlled by nerve growth factor receptor/trk binding sites for SHC and PLC.
EMBO J
13:1585-1590[Web of Science][Medline].
-
Patterson S,
Abel T,
Deuel T,
Martin K,
Rose J,
Kandel E
(1996)
Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice.
Neuron
16:1137-1145[Web of Science][Medline].
-
Raffioni S,
Bradshaw RA,
Buxser SE
(1993)
The receptors for nerve growth factor and other neurotrophins.
Annu Rev Biochem
62:823-850[Web of Science][Medline].
-
Raivich G,
Hellweg R,
Kreutzberger G
(1991)
NGF receptor-mediated reduction in axonal NGF uptake and retrograde transport following sciatic nerve injury and during regeneration.
Neuron
7:151-164[Web of Science][Medline].
-
Richardson P,
Riopelle R
(1984)
Uptake of nerve growth factor along peripheral and spinal axons of primary sensory neurons.
J Neurosci
4:1683-1689[Abstract].
-
Rohrer H,
Schafer T,
Korsching S,
Thoenen H
(1982)
Internalization of nerve growth factor by pheochromocytoma PC12 cells: absence of transfer to the nucleus.
J Neurosci
2:687-697[Abstract].
-
Segal R,
Greenberg M
(1996)
Intracellular signaling pathways activated by neurotrophic factors.
Annu Rev Neurosci
19:463-489[Web of Science][Medline].
-
Segal R,
Bhattacharyya A,
Rua L,
Alberta J,
Stephens R,
Kaplan D,
Stiles C
(1996)
Differential utilization of Trk autophosphorylation sites.
J Biol Chem
271:20175-20181[Abstract/Free Full Text].
-
Sheetz M,
Steuer E,
Schroer T
(1989)
The mechanism and regulation of fast axonal transport.
Trends Neurosci
12:474-478[Web of Science][Medline].
-
Snider WD,
Johnson EM
(1989)
Neurotrophic molecules.
Ann Neurol
26:489-506[Web of Science][Medline].
-
Soppet D,
Escandon E,
Maragos J,
Middlemas DS,
Reid SW,
Blair J,
Burton LE,
Stanton BR,
Kaplan DR,
Hunter T
(1991)
The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor.
Cell
65:895-903[Web of Science][Medline].
-
Sorkin A,
Waters C
(1993)
Endocytosis of growth factor receptors.
Bioessays
15:375-382[Web of Science][Medline].
-
Stephens R,
Loeb D,
Copelan T,
Pawson T,
Greene L,
Kaplan D
(1994)
Trk receptors use redundant signal transduction pathways involving SHC and PLC
1 to mediate NGF responses.
Neuron
12:691-705[Web of Science][Medline]. -
Vallee R,
Bloom G
(1991)
Mechanisms of fast and slow axonal transport.
Annu Rev Neurosci
14:59-92[Web of Science][Medline].
-
Vieria A,
Lamaze C,
Schmid S
(1996)
Control of EGF receptor signaling by clathrin-mediated endocytosis.
Science
274:2086-2089[Abstract/Free Full Text].
-
Vogel KS
(1993)
Development of trophic interactions in the vertebrate peripheral nervous system.
Mol Neurobiol
7:363-382[Web of Science][Medline].
This article has been cited by other articles:

|
 |

|
 |
 
J. S. Kroin, M. Takatori, J. Li, E.-Y. Chen, A. Buvanendran, and K. J. Tuman
Upregulation of Dorsal Horn Microglial Cyclooxygenase-1 and Neuronal Cyclooxygenase-2 After Thoracic Deep Muscle Incisions in the Rat
Anesth. Analg.,
April 1, 2008;
106(4):
1288 - 1295.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Cui, C. Wu, L. Chen, A. Ramirez, E. L. Bearer, W.-P. Li, W. C. Mobley, and S. Chu
One at a time, live tracking of NGF axonal transport using quantum dots
PNAS,
August 21, 2007;
104(34):
13666 - 13671.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Albers and B. M. Davis
The Skin as a Neurotrophic Organ
Neuroscientist,
August 1, 2007;
13(4):
371 - 382.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E. N. Ottem, L. A. Beck, C. L. Jordan, and S. M. Breedlove
Androgen-Dependent Regulation of Brain-Derived Neurotrophic Factor and Tyrosine Kinase B in the Sexually Dimorphic Spinal Nucleus of the Bulbocavernosus
Endocrinology,
August 1, 2007;
148(8):
3655 - 3665.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Woronowicz, S. R. Amith, K. De Vusser, W. Laroy, R. Contreras, S. Basta, and M. R. Szewczuk
Dependence of neurotrophic factor activation of Trk tyrosine kinase receptors on cellular sialidase
Glycobiology,
January 1, 2007;
17(1):
10 - 24.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Lin, C. Quevedo, N. E. Brewer, A. Bell, J. R. Testa, M. L. Grimes, F. D. Miller, and D. R. Kaplan
APPL1 Associates with TrkA and GIPC1 and Is Required for Nerve Growth Factor-Mediated Signal Transduction
Mol. Cell. Biol.,
December 1, 2006;
26(23):
8928 - 8941.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Gomes, C. Hampton, F. El-Sabeawy, S. L. Sabo, and A. K. McAllister
The Dynamic Distribution of TrkB Receptors before, during, and after Synapse Formation between Cortical Neurons.
J. Neurosci.,
November 1, 2006;
26(44):
11487 - 11500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Esper and J. A. Loeb
Rapid Axoglial Signaling Mediated by Neuregulin and Neurotrophic Factors
J. Neurosci.,
July 7, 2004;
24(27):
6218 - 6227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. B. Elmariah, M. A. Crumling, T. D. Parsons, and R. J. Balice-Gordon
Postsynaptic TrkB-Mediated Signaling Modulates Excitatory and Inhibitory Neurotransmitter Receptor Clustering at Hippocampal Synapses
J. Neurosci.,
March 10, 2004;
24(10):
2380 - 2393.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Pollock, R. Robichon, K. A. Boyd, K. A. Kerkel, M. Kramer, J. Lyles, R. Ambalavanar, A. Khan, D. R. Kaplan, R. W. Williams, et al.
TrkB Receptor Signaling Regulates Developmental Death Dynamics, But Not Final Number, of Retinal Ganglion Cells
J. Neurosci.,
November 5, 2003;
23(31):
10137 - 10145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Du, L. Feng, E. Zaitsev, H.-S. Je, X.-w. Liu, and B. Lu
Regulation of TrkB receptor tyrosine kinase and its internalization by neuronal activity and Ca2+ influx
J. Cell Biol.,
October 27, 2003;
163(2):
385 - 395.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Garcia, V. Forster, D. Hicks, and E. Vecino
In Vivo Expression of Neurotrophins and Neurotrophin Receptors Is Conserved in Adult Porcine Retina In Vitro
Invest. Ophthalmol. Vis. Sci.,
October 1, 2003;
44(10):
4532 - 4541.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. I. Carrasco and A. W. English
Neurotrophin 4/5 is required for the normal development of the slow muscle fiber phenotype in the rat soleus
J. Exp. Biol.,
July 1, 2003;
206(13):
2191 - 2200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. C. Bronfman, M. Tcherpakov, T. M. Jovin, and M. Fainzilber
Ligand-Induced Internalization of the p75 Neurotrophin Receptor: A Slow Route to the Signaling Endosome
J. Neurosci.,
April 15, 2003;
23(8):
3209 - 3220.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Jullien, V. Guili, E. A. Derrington, J.-L. Darlix, L. F. Reichardt, and B. B. Rudkin
Trafficking of TrkA-Green Fluorescent Protein Chimerae during Nerve Growth Factor-induced Differentiation
J. Biol. Chem.,
February 28, 2003;
278(10):
8706 - 8716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Jullien, V. Guili, L. F. Reichardt, and B. B. Rudkin
Molecular Kinetics of Nerve Growth Factor Receptor Trafficking and Activation
J. Biol. Chem.,
October 4, 2002;
277(41):
38700 - 38708.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Sherff and T. J. Carew
Behavioral, Cellular, and Molecular Analysis of Memory in Aplysia II: Long-Term Facilitation
Integr. Comp. Biol.,
August 1, 2002;
42(4):
736 - 742.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Cui, L. S. Tang, B. Hu, K.-F. So, and H. K. Yip
Expression of trkA, trkB, and trkC in Injured and Regenerating Retinal Ganglion Cells of Adult Rats
Invest. Ophthalmol. Vis. Sci.,
June 1, 2002;
43(6):
1954 - 1964.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Akbarian, M. Rios, R.-J. Liu, S. J. Gold, H.-F. Fong, S. Zeiler, V. Coppola, L. Tessarollo, K. R. Jones, E. J. Nestler, et al.
Brain-Derived Neurotrophic Factor Is Essential for Opiate-Induced Plasticity of Noradrenergic Neurons
J. Neurosci.,
May 15, 2002;
22(10):
4153 - 4162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Shao, W. Akmentin, J. J. Toledo-Aral, J. Rosenbaum, G. Valdez, J. B. Cabot, B. S. Hilbush, and S. Halegoua
Pincher, a pinocytic chaperone for nerve growth factor/TrkA signaling endosomes
J. Cell Biol.,
May 13, 2002;
157(4):
679 - 691.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Whitmarsh, C.-Y. Kuan, N. J. Kennedy, N. Kelkar, T. F. Haydar, J. P. Mordes, M. Appel, A. A. Rossini, S. N. Jones, R. A. Flavell, et al.
Requirement of the JIP1 scaffold protein for stress-induced JNK activation
Genes & Dev.,
September 15, 2001;
15(18):
2421 - 2432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bibel and Y.-A. Barde
Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system
Genes & Dev.,
December 1, 2000;
14(23):
2919 - 2937.
[Full Text]
|
 |
|

|
 |

|
 |
 
R. D. York, D. C. Molliver, S. S. Grewal, P. E. Stenberg, E. W. McCleskey, and P. J. S. Stork
Role of Phosphoinositide 3-Kinase and Endocytosis in Nerve Growth Factor-Induced Extracellular Signal-Regulated Kinase Activation via Ras and Rap1
Mol. Cell. Biol.,
November 1, 2000;
20(21):
8069 - 8083.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E. C. Beattie, C. L. Howe, A. Wilde, F. M. Brodsky, and W. C. Mobley
NGF Signals through TrkA to Increase Clathrin at the Plasma Membrane and Enhance Clathrin-Mediated Membrane Trafficking
J. Neurosci.,
October 1, 2000;
20(19):
7325 - 7333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-z. Zhang, D. B. Moheban, B. R. Conway, A. Bhattacharyya, and R. A. Segal
Cell Surface Trk Receptors Mediate NGF-Induced Survival While Internalized Receptors Regulate NGF-Induced Differentiation
J. Neurosci.,
August 1, 2000;
20(15):
5671 - 5678.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. A. Tsui-Pierchala and D. D. Ginty
Characterization of an NGF-P-TrkA Retrograde-Signaling Complex and Age-Dependent Regulation of TrkA Phosphorylation in Sympathetic Neurons
J. Neurosci.,
October 1, 1999;
19(19):
8207 - 8218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. L. Watson, H. M. Heerssen, D. B. Moheban, M. Z. Lin, C. M. Sauvageot, A. Bhattacharyya, S. L. Pomeroy, and R. A. Segal
Rapid Nuclear Responses to Target-Derived Neurotrophins Require Retrograde Transport of Ligand-Receptor Complex
J. Neurosci.,
September 15, 1999;
19(18):
7889 - 7900.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. T. Drake, T. A. Milner, and S. L. Patterson
Ultrastructural Localization of Full-Length trkB Immunoreactivity in Rat Hippocampus Suggests Multiple Roles in Modulating Activity-Dependent Synaptic Plasticity
J. Neurosci.,
September 15, 1999;
19(18):
8009 - 8026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Bowman, R. S. Patel-King, S. E. Benashski, J. M. McCaffery, L. S.B. Goldstein, and S. M. King
Drosophila roadblock and Chlamydomonas Lc7: A Conserved Family of Dynein-Associated Proteins Involved in Axonal Transport, Flagellar Motility, and Mitosis
J. Cell Biol.,
July 12, 1999;
146(1):
165 - 180.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. K. Binder, M. J. Routbort, and J. O. McNamara
Immunohistochemical Evidence of Seizure-Induced Activation of trk Receptors in the Mossy Fiber Pathway of Adult Rat Hippocampus
J. Neurosci.,
June 1, 1999;
19(11):
4616 - 4626.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Chang and S. V. Popov
Long-range signaling within growing neurites mediated by neurotrophin-3
PNAS,
March 30, 1999;
96(7):
4095 - 4100.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. U. Saragovi, W. Zheng, S. Maliartchouk, G. M. DiGugliemo, Y. R. Mawal, A. Kamen, S. B. Woo, A. C. Cuello, T. Debeir, and K. E. Neet
A TrkA-selective, Fast Internalizing Nerve Growth Factor-Antibody Complex Induces Trophic but Not Neuritogenic Signals
J. Biol. Chem.,
December 25, 1998;
273(52):
34933 - 34940.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Dib-Hajj, J. A. Black, T. R. Cummins, A. M. Kenney, J. D. Kocsis, and S. G. Waxman
Rescue of alpha -SNS Sodium Channel Expression in Small Dorsal Root Ganglion Neurons After Axotomy by Nerve Growth Factor In Vivo
J Neurophysiol,
May 1, 1998;
79(5):
2668 - 2676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Fawcett, S. X. Bamji, C. G. Causing, R. Aloyz, A. R. Ase, T. A. Reader, J. H. McLean, and F. D. Miller
Functional Evidence that BDNF Is an Anterograde Neuronal Trophic Factor in the CNS
J. Neurosci.,
April 15, 1998;
18(8):
2808 - 2821.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-T. Ma, T. Hsieh, M. E. Forbes, J. E. Johnson, and D. O. Frost
BDNF Injected into the Superior Colliculus Reduces Developmental Retinal Ganglion Cell Death
J. Neurosci.,
March 15, 1998;
18(6):
2097 - 2107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-D. Delcroix, S. Averill, K. Fernandes, D. R. Tomlinson, J. V. Priestley, and P. Fernyhough
Axonal Transport of Activating Transcription Factor-2 Is Modulated by Nerve Growth Factor in Nociceptive Neurons
J. Neurosci.,
September 15, 1999;
19(18):
RC24 - RC24.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Yano, F. S. Lee, H. Kong, J.-Z. Chuang, J. C. Arevalo, P. Perez, C.-H. Sung, and M. V. Chao
Association of Trk Neurotrophin Receptors with Components of the Cytoplasmic Dynein Motor
J. Neurosci.,
February 1, 2001;
21(3):
RC125 - RC125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Qin, R. S. Vulapalli, S. Y. Stevens, and C.-S. Liang
Loss of cardiac sympathetic neurotransmitters in heart failure and NE infusion is associated with reduced NGF
Am J Physiol Heart Circ Physiol,
January 1, 2002;
282(1):
H363 - H371.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|